Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 combination in advanced urothelial carcinoma
NCT06639347Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-A2102 in urothelial carcinoma (UC), sponsored by Hengrui Therapeutics. Started Nov 2024; status: recruiting.
02
Drugs
SHR-A2102
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06639347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06639347.